Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Browse by Series:

FDA Approval for Lutathera in Neuroendocrine Tumors

Gina Columbus
Published: Friday, Jan 26, 2018



Gina Columbus reports on the FDA approval to Lutathera (177Lutetium DOTA-octreotate) for the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
SELECTED
LANGUAGE
Slider Left
Slider Right


Gina Columbus reports on the FDA approval to Lutathera (177Lutetium DOTA-octreotate) for the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x